ICCC · Immucell Corp /De/ - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.36M | - | $6.01M | $6.44M | $7.26M | - | $6.01M | - | - | - |
| Cost of Revenue | $5.70M | - | $3.14M | $3.63M | $4.71M | - | $4.43M | $4.24M | $4.96M | - |
| Gross Profit | $4.66M | - | $2.36M | $2.82M | $3.35M | - | $1.58M | $1.23M | $2.30M | - |
| R&D | $317.7K | - | $694.3K | $831.9K | $756.8K | - | $786.1K | $1.03M | $1.26M | - |
| SG&A | $1.14M | - | $729.4K | $720.4K | $622.8K | - | $528.3K | $601.6K | $531.9K | - |
| Total Operating Expenses | $2.69M | - | $2.34M | $2.25M | $2.24M | - | $2.16M | $2.62M | $2.60M | - |
| D&A | $531.5K | - | $708.7K | $663.5K | $671.2K | - | $670.3K | $666.2K | $662.5K | - |
| Operating Income | $1.97M | - | $20.1K | $569.6K | $1.12M | - | ($574.9K) | ($1.39M) | ($300.1K) | - |
| Interest Expense | $127.9K | - | $144.1K | - | - | - | $144.1K | $142.4K | $146.0K | - |
| Income Tax | $12.5K | - | $4.5K | $1.9K | $1.9K | - | $1.3K | $1.3K | $1.3K | - |
| Net Income | $1.94M | - | ($139.7K) | $501.9K | $1.45M | - | ($701.7K) | ($1.53M) | ($437.9K) | - |
| EPS - Basic | $0.21 | - | ($0.02) | $0.06 | $0.16 | - | ($0.09) | ($0.20) | ($0.06) | - |
| EPS - Diluted | $0.21 | - | ($0.02) | $0.06 | $0.16 | - | ($0.09) | ($0.20) | ($0.06) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.81M | $3.81M | $3.89M | $6.00M | $4.60M | $3.76M | $3.81M | $1.32M | $960.3K | $978.7K |
| Accounts Receivable | $2.69M | $3.42M | $2.55M | $2.38M | $3.35M | $3.77M | $2.31M | $1.95M | $2.62M | $2.19M |
| Inventory | $8.67M | $9.27M | $9.80M | $8.29M | $7.36M | $7.11M | $7.46M | $7.30M | $7.15M | $7.81M |
| Accounts Payable | $935.1K | $792.2K | $949.7K | $884.9K | $960.1K | $934.9K | $876.8K | $437.0K | $725.6K | $874.6K |
| Current Assets | $18.86M | $16.94M | $16.83M | $17.14M | $15.92M | $15.04M | $13.89M | $10.79M | $11.35M | - |
| Total Assets | $44.11M | $42.53M | $45.73M | $46.72M | $45.62M | $45.10M | $44.45M | $41.86M | $43.05M | $43.81M |
| Current Liabilities | $3.91M | $3.98M | $4.00M | $4.45M | $3.87M | $4.41M | $4.47M | $4.56M | $4.18M | $4.20M |
| Long-term Debt | $7.07M | $7.49M | $7.90M | $8.26M | $10.25M | - | - | - | - | - |
| Total Liabilities | $14.97M | $15.48M | $15.93M | $16.85M | $16.63M | $17.58M | $18.04M | $18.40M | $18.41M | $18.82M |
| Stockholders' Equity | $29.14M | $27.06M | $29.80M | $29.87M | $28.99M | $27.52M | $26.41M | $23.46M | $24.64M | $24.99M |
| Retained Earnings | ($13.26M) | ($15.20M) | ($12.35M) | ($12.21M) | ($12.72M) | ($14.16M) | ($14.68M) | ($13.98M) | ($12.44M) | ($12.01M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.57M | - | - | - | $1.57M | - | - | - | $418.5K | - |
| Investing Cash Flow | ($167.2K) | - | - | - | ($329.1K) | - | - | - | ($70.4K) | - |
| Financing Cash Flow | ($400.0K) | - | - | - | ($403.6K) | - | - | - | ($366.5K) | - |
| CapEx | $177.2K | - | - | - | $329.1K | - | - | - | $70.4K | - |
| Free Cash Flow | $3.40M | - | - | - | $1.24M | - | - | - | $348.1K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 45.0% | - | 39.3% | 43.7% | 46.2% | - | 26.3% | - | - | - |
| Operating margin | 19.0% | - | 0.3% | 8.8% | 15.4% | - | -9.6% | - | - | - |
| EBITDA margin | 24.1% | - | 12.1% | 19.1% | 24.6% | - | 1.6% | - | - | - |
| Net margin | 18.7% | - | -2.3% | 7.8% | 19.9% | - | -11.7% | - | - | - |
| Free cash flow margin | 32.8% | - | - | - | 17.2% | - | - | - | - | - |
| FCF / Net income | 1.75 | - | - | - | 0.86 | - | - | - | -0.80 | - |
| R&D / Revenue | 3.1% | - | 11.5% | 12.9% | 10.4% | - | 13.1% | - | - | - |
| SG&A / Revenue | 11.0% | - | 12.1% | 11.2% | 8.6% | - | 8.8% | - | - | - |
| Effective tax rate | 0.6% | - | - | 0.4% | 0.1% | - | - | - | - | - |
| Return on assets | 4.4% | - | -0.3% | 1.1% | 3.2% | - | -1.6% | -3.7% | -1.0% | - |
| Return on equity | 6.7% | - | -0.5% | 1.7% | 5.0% | - | -2.7% | -6.5% | -1.8% | - |
| Return on invested capital | 5.4% | - | 0.0% | 1.5% | 2.8% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.82 | 4.26 | 4.21 | 3.85 | 4.12 | 3.41 | 3.11 | 2.37 | 2.71 | - |
| Quick ratio | 2.60 | 1.93 | 1.76 | 1.99 | 2.21 | 1.80 | 1.44 | 0.77 | 1.00 | - |
| Cash ratio | 1.74 | 0.96 | 0.97 | 1.35 | 1.19 | 0.85 | 0.85 | 0.29 | 0.23 | 0.23 |
| Leverage | ||||||||||
| Debt / Equity | 0.24 | 0.28 | 0.27 | 0.28 | 0.35 | - | - | - | - | - |
| Debt / Assets | 0.16 | 0.18 | 0.17 | 0.18 | 0.22 | - | - | - | - | - |
| Debt / EBITDA | 2.83 | - | 10.84 | 6.70 | 5.73 | - | - | - | - | - |
| Interest coverage | 15.4x | - | 0.1x | - | - | - | -4.0x | -9.7x | -2.1x | - |
| Equity multiplier | 1.51 | 1.57 | 1.53 | 1.56 | 1.57 | 1.64 | 1.68 | 1.78 | 1.75 | 1.75 |
| Liabilities / Assets | 0.34 | 0.36 | 0.35 | 0.36 | 0.36 | 0.39 | 0.41 | 0.44 | 0.43 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | 0.23 | - | 0.13 | 0.14 | 0.16 | - | 0.14 | - | - | - |
| Inventory turnover | 0.66 | - | 0.32 | 0.44 | 0.64 | - | 0.59 | 0.58 | 0.69 | - |
| Days sales outstanding | 95d | - | 155d | 135d | 168d | - | 140d | - | - | - |
| Days inventory outstanding | 555d | - | 1138d | 835d | 570d | - | 615d | 628d | 526d | - |
| Days payable outstanding | 60d | - | 110d | 89d | 74d | - | 72d | 38d | 53d | - |
| Cash conversion cycle | 591d | - | 1183d | 880d | 664d | - | 683d | - | - | - |
| Valuation | ||||||||||
| P / E | 30.1x | - | - | 116.0x | 29.9x | - | - | - | - | - |
| P / B | 2.0x | - | 1.9x | 2.1x | 1.5x | - | 1.1x | 1.6x | 1.7x | - |
| P / S | 5.5x | - | 9.4x | 9.8x | 5.9x | - | 4.9x | - | - | - |
| EV / EBITDA | 23.0x | - | 83.1x | 52.8x | 27.2x | - | 270.6x | - | 110.7x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 42.7% | - | 0.0% | - | - | - | 11.4% | - | - | - |
| Revenue CAGR (3y) | - | - | 5.3% | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 38.9% | - | 49.2% | 129.0% | 46.1% | - | 25.0% | 17.9% | 663.1% | - |
| Operating income growth (YoY) | 76.2% | - | - | - | - | - | 51.4% | -6.3% | 86.7% | - |
| Net income growth (YoY) | 34.2% | - | 80.1% | - | - | - | 25.4% | -11.0% | 81.1% | - |
| EPS growth (YoY) | 31.2% | - | 77.8% | - | - | - | 25.0% | -11.1% | 80.0% | - |
| EPS CAGR (3y) | - | - | - | - | 21.1% | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 172.8% | - | - | - | 257.5% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | -6.3% | - |
| Book value growth (YoY) | 0.5% | -1.7% | 12.8% | 27.3% | 17.7% | 10.1% | 1.5% | -12.7% | -12.5% | -17.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$27.64M totalCorporate Segment Scours$27.45M · 99.3%
Corporate Segment Mastitis$196.4K · 0.7%
Geographic
$27.64M totalAmericas$24.39M · 88.2%
Non Us$3.25M · 11.8%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing IMMUCELL CORP /DE/ against the 5 most active filers in the same SIC group.